Therapeutic Potential of a Novel Polyherbal Formulation: Assessments in Exogenous and Endogenous Dyslipidemia Models

This chapter was designed to evaluate the effects of a novel herbal medicine called “GANMO” on experimental animal models. Dyslipidemia refers to the excess status of fatty substances including cholesterol, triglyceride, low-density lipoprotein (LDL-C), and decreased high-density lipoprotein cholesterol (HDL-C) in the bloodstream. In this study, we used Propylthiouracil (Rieserstat®)50mg, Cholesterol (Merk-Germany), Acid Cholic, Poloxamer 407, (Sigma–Singapore), Atorvastatin 10mg (Stellapharm J.V. Co., Ltd), Peanut oil (Vietnam). Our finding showed that TG concentration increased substantially by 6.8-fold, TC levels and non-HDL-C concentrations increased by 2.9-fold and 4.1-fold respectively. Base on the success of the P-407 induced hyperlipidemia model, the effects of the GANMO tablet could be evaluated precisely. GANMO significantly reduced serum total cholesterol (TC) and non-high-density lipoprotein cholesterol (non-HDL-C) levels in both models at both doses when compared to the model group. Rats given high doses of GANMO had higher levels of HDL cholesterol than rats given low doses. GANMO at both doses reduced substantially TG level in the endogenous hyperlipidemia model. In conclusion, GANMO tablets posed a positive effect on serum lipid modulations in dyslipidemia models.